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Hypoxia in the Eye: A Two-Sided Coin
Christian Grimm1 and Gabriel Willmann2
Abstract
Grimm, Christian, Gabriel Willman. Hypoxia in the eye: A two-sided coin. High Alt Med Biol. 13:169—175, 2012.—
Tissue oxygenation in general and hypoxia in particular are important regulators of retinal physiology and
pathophysiology. Reduced oxygen tension and hypoxia-inducible transcription factors along with some of their
target genes are critically involved in retinal development, and especially in the generation of a normal retinal
vasculature. Well-timed hypoxia is thus vital for the young eye to establish proper retinal function and vision.
However, when hypoxia is ill-timed, reduced oxygen tension may be associated with the development of retinal
pathologies, including retinopathy of prematurity, diabetic retinopathy, glaucoma, age-related macular degener-
ation, or high altitude retinopathy. Here, reduced oxygen tension activates a hypoxic response that culminates in
an increased expression of vascular endothelial growth factor. This causes pathological neovascularization of the
delicate neuronal retina, a process that may ultimately lead to loss of vision. In contrast, preconditioning by well-
defined and controlled short-term hypoxia is not devastating for the retina but instead induces a molecular
response that provides protection to neuronal cells. Detailed investigation of hypoxic mechanisms during devel-
opment and adulthood may thus reveal factors, which may be targeted by therapeutic approaches to save and
preserve vision in patients.
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Introduction
Visible light has to reach the light-sensitive photore-ceptors in the retina efficiently and with minimal scat-
tering to ensure maximal sensitivity and visual acuity. Thus,
cornea, lens, and vitreous are clear and avascular structures
that allow maximal penetrance for those wavelengths of light
useful to the visual system. Although these structures do not
contain blood vessels in the adult eye, oxygen is nevertheless
an important regulator of their physiology. Insufficient oxy-
genation of the cornea, for example, has been associated with
pathological vascularization influencing tissue integrity and
visual acuity (Safvati et al., 2009). Increased oxygenation of
the lens, on the other hand, may reduce lens clarity and thus
sensitivity of the visual system (McNulty et al., 2004). Al-
though control of oxygenation in these tissues is of high im-
portance for the process of vision, this review will focus on the
significance of fine-tuned oxygen levels for the retina during
development and in the adult eye. Disturbed oxygenation is
associated with the pathology of several blinding diseases of
the retina (Fig. 1A–1D), and may also impact on retinal
function and tissue integrity at high altitudes.
Hypoxia in Retinal Pathologies:
The Bad Side of the Coin
High altitude-associated changes
Reduced oxygen levels at high altitude correlate with sev-
eral retinal changes in human subjects. Studies in mountain-
eers revealed that an ascent to high altitude may cause
morphological and functional changes of the retina, such as
optic disc swelling, changes of macular function including
color discrimination, altered retinal and choroidal blood flow,
and retinal hemorrhages (Frayser et al., 1970; Wiedman, 1975;
Pavlidis et al., 2005; Morris et al., 2007; Bosch et al., 2008, 2009;
Willmann et al., 2010, 2011; Ho et al., 2011; Fischer et al., 2012).
While some of these changes present physiological adaptive
mechanisms to high altitude exposure such as increased blood
flow and increased tortuosity of blood vessels, others present
potentially pathological changes to hypoxia, such as optic disc
swelling or retinal hemorrhages. Interestingly, a significant
portion of high altitude mountaineers develop detectable
retinal hemorrhages only after their return to base camp from
very high altitudes (Barthelmes et al., 2011). However, most of
the observed changes are reversible with time, suggesting that
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the normal retina has an intrinsically protective system that
has the capacity to cope with and adapt to transient changes in
oxygen levels. However, this system may not be sufficient to
protect retinal integrity and function in all situations. Espe-
cially if hypoxia lasts for an extended period of time, or if
hypoxia occurs in the presence of additional stress factors
such as certain gene mutations and pre-existing systemic or
ocular disease, changing oxygen levels may be devastating for
the retina and thus for visual function in human patients. It is
clear, for example, that reduced tissue oxygenation negatively
influences retinopathy of prematurity (ROP), diabetic reti-
nopathy (DR), age-related macular degeneration (AMD), and
glaucoma.
Retinopathy of prematurity
Changes in retinal oxygenation in preterm infants are as-
sociated with ROP, which accounts for 6% to 18% of visual
impairment in children (Gilbert et al., 1997). After birth,
newborns experience oxygen levels that are hyperoxic relative
to the in utero situation (Mintz-Hittner and Best, 2009). The
retinas of children born at term tolerate this sudden change in
oxygenation since the retinal vasculature is already fully de-
veloped. In infants born prematurely, however, the relative
hyperoxic environment may reduce production of hypoxia-
related pro-angiogenic factors and prevent complete matu-
ration of the retinal vasculature, or even cause vessel dropout.
Relative tissue hypoxia, which may follow this hyperoxic
phase as soon as retinal cells start to function, is thought to be
then responsible for abnormal vessel growth leading to neo-
vascularization, and eventually to scarring, formation of
hemorrhages, and/or retinal detachment (Mintz-Hittner and
Best, 2009). The molecular response to this second phase of
ROP centers around activation of hypoxia-inducible tran-
scription factors (HIFs), which regulate expression of various
genes important for vessel growth such as vascular endo-
thelial growth factor (VEGF), erythropoietin (EPO), and
others (Lee et al., 2004). Although local anti-VEGF therapy
may significantly improve disease outcome, future ap-
proaches to further increase efficacy of treatment may need to
target additional pro- or inhibitory angiogenic factors (Table
1), or upstream mechanisms regulating expression of these
factors. Controlled destabilization of HIFA subunits, for ex-
ample, might be a possible way to simultaneously influence
expression of most genes regulating neovascular vessel
growth, and may thus have a larger inhibitory impact on
disease progression.
Nevertheless, until today the mainstay of ROP treatment
remains laser therapy, while the off-label use of anti-VEGF
antibodies has only been shown to be superior compared to
laser treatment in ROP zone I. Advantages of anti-VEGF an-
tibodies include the potential induction of neovascular re-
gression, as well as the development of a more physiological
vasculature (Mintz-Hittner and Kuffel, 2008; Stahl et al.,
2011).
Diabetic retinopathy
DR affects a large percentage of patients suffering from
diabetes mellitus. Symptoms include blurred vision, shadows
FIG. 1. The mountain village Medergen (Switzerland, 2000 meters above sea level) as seen by a person with normal eyesight
(A), and by patients affected by diabetic retinopathy (B), age-related macular degeneration (C), or glaucoma (D).
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and/or missing areas of vision (Fig. 1B), retinal detachments,
vitreous hemorrhages, and more. Diabetic retinopathy is a
micro-angiopathy and among the most frequent causes for
severe visual impairment in industrialized nations (Ferris
et al., 1999; Kocur and Resnikoff, 2002). The initial phase of DR
is characterized by microvascular occlusion initiated by hy-
perglycemia. This results in capillary nonperfusion, fol-
lowed by retinal hypoxia, which leads to arteriovenous
shunts characterized by vessel dropout and later by neo-
vascularization. Clinical lesions often found in background
diabetic retinopathy include micro-aneurysms with leakage
or occlusion, retinal hemorrhages, macular edema, and
hard exudates. The primary feature of the proliferative
phase of the disease is neovascularization caused by ex-
tensive retinal hypoxia, with neovascularization being the
result of an interaction between various pro-angiogenic
factors with angiogenic inhibitors (Table 1) (Frank, 2004;
Antonetti et al., 2012). It is important to note that stimula-
tion or inhibition by these factors largely depends on the
disease state. However, since VEGF plays a key role in
disease development, novel anti-VEGF therapeutic strate-
gies are now able to fulfill the previously unmet medical
need for a treatment, which is superior to traditional laser
photocoagulation for diabetic macular edema, for example
(Bandello et al., 2012).
Although not fully elucidated, alterations in retinal hemo-
dynamics with reduced blood flow in the retina may be an
important factor in addition to hyperglycemia for the initia-
tion of DR. Local or global changes in retinal oxygenation may
cause the development of hypoxic areas as the disease pro-
gresses (Arden and Sivaprasad, 2011). As in ROP, activation
of HIF transcription factors may then be responsible for the
production of angiogenic proteins and thus for the develop-
ment of a neovascular response.
Age-related macular degeneration
AMD is characterized by distorted, blurred, and reduced
central vision (Fig. 1C). Affected individuals have difficulties
reading, watching television, and recognizing people’s faces.
AMD is the leading cause of visual impairment and blindness
in elderlies in the developed world (Gehrs et al., 2006). In
general, AMD can be of the dry or of the wet form. In the dry
form, also called geographic atrophy, retinal pigment epi-
thelial (RPE) cells and photoreceptors in the central retina
covering the macula degenerate, leading to loss of central high
acuity vision. The wet form, which may or may not follow the
dry form, is characterized by neovascularization of the retina
with vessels originating from the choroid penetrating the RPE
and growing into the neuronal retina. As in DR, alterations in
ocular blood flow and hemodynamics, as well as reduced
perfusion of the choriocapillaries, have been described. In
addition, thickening of Bruch’s membrane, alterations of RPE
cells with the accumulation of lipofuscin, and the formation of
drusen may reduce diffusion of oxygen from the choroid to
the retina (Schlingemann, 2004; Terman and Brunk, 2004).
This may lead to reduced oxygen tension causing the activa-
tion of a hypoxic response, which may lead to the develop-
ment of neovascular complications. In this response, HIF
factors may again be the driving force controlling initiation
and progression of the devastating vessel growth (Inoue et al.,
2007; Sheridan et al., 2009). The main pro-angiogenic factor in
wet AMD seems to be VEGF. Anti-VEGF therapies success-
fully slow or even prevent neovascularization in AMD pa-
tients. Targeting HIF1 prevented production of VEGF in RPE
cells in vitro and reduced neovascular vessel growth in animal
models in vivo (Zhang et al., 2007, 2010; Yoshida et al., 2010),
suggesting that hypoxia-induced HIF1 might be responsible
for the development of wet AMD and loss of vision.
Glaucoma
Glaucoma is the second leading cause of blindness world-
wide (Quigley and Broman, 2006). The death of retinal gan-
glion cells in glaucoma may disconnect the retina from the
visual cortex, preventing signal transmission and formation of
useful vision in patients. Patients may initially experience
blurred and cloudy vision, especially in the periphery (Fig.
1D). If untreated, glaucoma may lead to complete blindness.
Vascular abnormalities and altered blood flow at the optic
nerve head may lead to local hypoxia, accelerating neuronal
cell death in patients (Osborne et al., 2001; Flammer et al.,
2002). Again, HIF1 is thought to be involved in the pathology
of glaucoma: increased presence of HIF1A was found in
glaucomatous eyes and localization of this protein correlated
with regions of visual field defects (Tezel and Wax, 2004).
Table 1. Selected Key Angiogenic Factors and Inhibitors in the Retina
Factor Name Activity Reference
VEGF vascular endothelial growth factor pro-angiogenic (Witmer et al., 2003)
EPO erythropoietin pro-angiogenic (Watanabe et al., 2005)
IGF1 insulin-like growth factor 1 pro-angiogenic (Simo et al., 2006)
PGF placental growth factor pro-angiogenic (Carmeliet et al., 2001)
PDGF platelet derived growth factor pro-angiogenic (Simo et al., 2006)
SDF stromal-cell derived factor pro-angiogenic (Lima e Silva et al., 2007)
HGF hepatocyte growth factor pro-angiogenic (Colombo et al., 2007)
ANG2 angiopoietin 2 pro-angiogenic (Hackett et al., 2002)
bFGF basic fibroblast growth factor pro-angiogenic (Wong et al., 2001)
CTGF conecting tissue growth factor pro-angiogenic (Kuiper et al., 2004)
TGF transforming growth factor pro-angiogenic (Spranger et al., 1999)
ANP atrial natrium peptide pro-angiogenic (Lara-Castillo et al., 2009)
Angiostatin angiostatin inhibitory (Spranger et al., 2000)
Endostatin endostatin inhibitory (Noma et al., 2002)
TSP-1 thrombospondin inhibitory (Sargiannidou et al., 2001)
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Hypoxia in Retinal Development:
The Good Side of the Coin
Cells of the retina may experience a period of relative
hypoxia before the capillary network in the vascular plexi is
established and functional. This has mostly been investigated
in mice and rats in which final retinal and vascular develop-
ment occurs postnatally. At birth, the mouse retina is avas-
cular and three vascular plexi develop from the optic nerve
head in a radial fashion within the first 2 weeks of life. Local
hypoxia may control production of VEGF, which is essential
for the primary vascular plexus in the nerve fiber layer to
develop. VEGF is thought to be primarily produced by as-
trocytes (West et al., 2005), but ganglion cells (Sapieha et al.,
2008) may also contribute to the formation of a VEGF gradient
with highest concentrations in the initially avascular periph-
eral retina (Stone et al., 1995). Although VEGF may be most
important for development of the primary vascular plexus,
factors such as insulin-growth factor 1, placental growth fac-
tor, leukemia inhibitory factor, and others play a role as well
(Caprara and Grimm, 2012). Similar to the formation of the
primary plexus, hypoxia-driven expression of VEGF seems
crucial for angiogenic sprouting preceding formation of the
deeper plexi. For this step of vascular development, VEGF is
expressed by cells of the inner nuclear layer, presumably by
Muller glia cells (Stone et al., 1995). Developmental hypoxia
and VEGF expression has also been described for the primate
retina (Sandercoe et al., 2003), suggesting that the mechanisms
governing retinal vascular development might be well con-
served.
Since expression of VEGF is mainly controlled by HIF
transcription factors, HIFs might be strongly involved in the
regulation of the vasculature in the retina. Furthermore, it has
been suggested that developmental hypoxia may also par-
ticipate in controlling the number of retinal neurons through
regulating the physiological process of developmental apo-
ptosis or programmed cell death (Maslim et al., 1997; Mervin
and Stone, 2002). Thus, it seems important that oxygen levels
are kept within a physiological range to ensure proper spatial
and timely activation of HIFs and their downstream target
genes, especially during development of the retina. Disturb-
ing this fine-tuned system may profoundly influence retinal
architecture and thus the functional performance of the tissue
with strong consequences for vision. It may therefore not be
surprising that mice with a conditional knockout of Hif1a in
most cells of the peripheral retina do not develop a normal
retinal vasculature. In the absence of HIF1A protein, the in-
termediate vascular plexus does not form, whereas the pri-
mary and the deep plexi are less affected. The architecture and
cellular composition of the neuronal retina, however, seems
normal. Interestingly, lack of HIF1A leads to an increased
expression and activation of HIF2A, probably as a compen-
satory reaction. As a consequence, Epo levels are strongly el-
evated in these mice (Caprara et al., 2011).
Not only a reduced (lack of HIF1A), but also an over-
stimulated hypoxic response disturbs retinal development.
Von Hippel Lindau (VHL) protein is a main factor in the
degradation of HIFA proteins in normoxic conditions. Lack of
VHL leads to the stabilization and functional activation of
HIF1 and HIF2, even at normal oxygen levels (Haase et al.,
2001). Deletion of Vhl in the developing retina generates a
sustained and misregulated hypoxia-like molecular response
with the activation of HIF1 and HIF2. This leads to severe
consequences for the retinal vasculature and the neuronal
tissue. The embryonic vasculature in the vitreous does not
regress and the retinal vasculature does not develop correctly
(Kurihara et al., 2010; Lange et al., 2011a). Vascular plexi are
severely disturbed and vessels penetrate all cell layers, in-
cluding the photoreceptor layer. Mis-regulated angiogenic
factors include Vegf, Epo, and others. Since exogenous appli-
cation of a VEGF receptor (FLT1) that binds and inactivates
VEGF prevents most of these changes, mis-expression of
HIF-controlled VEGF seems responsible for the observed al-
terations. This is further supported by the rescue of the phe-
notype by HIF1 ablation (Kurihara et al., 2010). The vascular
abnormalities also induce severe retinal degeneration with
loss of most neurons, leading to a strong reduction in retinal
function and thus in vision (Lange et al., 2011a).
In conclusion, physiological hypoxia is required for proper
development of the retinal vasculature and tissue architec-
ture. Only if the hypoxic response system can react properly
to changes in tissue oxygenation, the retina will develop into a
mature, well-structured, and functional organ. Thus, physio-
logical hypoxia is a critical environmental clue and is essential
for the formation of a functional visual system. That it is this
hypoxic clue and not only an intrinsically activated genetic
program that regulates development of the vasculature is
established with experiments involving exposure of newborn
mice to hyperoxia to prevent formation of physiological tissue
hypoxia. This treatment prevents activation of HIF tran-
scription factors, demonstrating that their normal develop-
mental activation is not due to a developmental program
initiated at specified time points after birth, but rather to al-
terations in tissue oxygenation. Hyperoxia not only prevents
HIF activation but also arrests the formation of retinal blood
vessels and even leads to vessel dropout in wild type mice.
Reactivation of the HIF system after reduction of oxygen
levels leads to neovascular changes and loss of neuronal cells
(Smith et al., 1994). Such experiments clearly demonstrate that
hypoxia provides important environmental signaling cues
that are vital for retinal physiology and function.
Hypoxia in Retinal Neuroprotection:
Another Good Side of the Coin
Although long-lasting hypoxia is devastating and may lead
to retinal degeneration and loss of vision (see above), short-
term hypoxic exposure can precondition the tissue and
prepare it to cope with a subsequent toxic insult. Cells and
animals can be preconditioned by a temporary reduction of
oxygen concentrations in the cell culture medium or breathing
air, respectively. It has been shown that preconditioning of
mice protects the retina against ischemic-reperfusion injury
(Roth et al., 1998), and against degeneration of photoreceptors
after exposure to bright light (Grimm et al., 2002). The un-
derlying molecular mechanisms are unclear but locally pro-
duced EPO may be part of the protection. Recombinant EPO
delivered by local or systemic injections, or by viral-mediated
gene transfer can provide partial protection for photorecep-
tors in some but not all situations (Grimm et al., 2002, 2004;
Rex et al., 2004, 2009). This may suggest that neuroprotective
factors in addition to EPO are produced during or after the
period of hypoxic preconditioning. The identification of those
factors might provide the basis for an efficient therapeutic
approach to treat human patients suffering from retinal de-
generation. Due to the short-lived effect of hypoxic pre-
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conditioning, it is not possible to test whether the treatment
would also protect against slower degenerations induced by
gene mutations. It is also not clear whether the combination of
factors induced by hypoxic preconditioning would be capable
to protect cells in all situations. Erythropoietin alone at least is
not. Constitutive overexpression of Epo provides some pro-
tection against light damage but not against degeneration
induced by a mutation in rod opsin or a mutation in rod
phosophdiesterase (Grimm et al., 2004). Direct application of
EPO or systemic expression of Epo from a virally transferred
gene, however, protects photoreceptors in the presence of a
mutation in the peripherin gene (Rex et al., 2009; Sullivan
et al., 2011).
Analysis of the retinal transcriptome showed that hypoxic
preconditioning differentially regulates a large number of
genes, but factors responsible for protection have not yet been
defined (Thiersch et al., 2008). It seems clear, however, that
expression of HIF1-regulated genes in photoreceptors is not
essential for autocrine protection (Thiersch et al., 2009), sug-
gesting either that protective factors are produced by other
classes of retinal cells to act in trans on photoreceptors, or that
factors controlled by HIF2 (or by other transcription factors
differentially regulated by hypoxia) are needed by photore-
ceptors to survive light exposure. Possibly, full protection is
only achieved if both autocrine and paracrine factors are
acting together. Deletion of VHL from rod photoreceptor cells
induces a hypoxia-like response in normoxia with the acti-
vation of HIF1, HIF2, and STAT3, and protects photorecep-
tors from light damage. However, protection is only transient
(Lange et al., 2011b), again arguing that a hypoxic response
restricted to photoreceptors participates in the protection but
is not sufficient for full protection.
The response to reduced oxygen tension may not be solely
determined by the stabilization of HIF transcription factors.
Increasing evidence suggests that epigenetic mechanisms
may also be involved in the regulation of HIF-mediated gene
transcription. Retinas tolerating ischemia contained increased
levels of trimethylated histone H3 and mono-ubiquitinated
histone H2A (Stowell et al., 2010), both of which are impli-
cated in epigenetic transcriptional regulation (Bantignies and
Cavalli, 2006). In addition, DNase-1 hypersensitive areas ob-
viously allow facilitated binding of HIF transcription factors
to their respective binding sites in promoters of target genes
(Schodel et al., 2011), suggesting that epigenetic mechanisms
are important regulators of the hypoxic response in a variety
of situations.
Conclusions and Outlook
The retina is one of the most metabolically active tissues of
the body. Photoreceptor cells consume up to 108 ATP mole-
cules per second in darkness (Okawa et al., 2008), and cells of
the RPE are among the most active phagocytes of the body
(Reme, 2000). Thus, proper function of the adult retina re-
quires that cells are sufficiently supplied with nutrients and
oxygen. Any alterations in oxygenation levels may have
devastating consequences for vision if no adequate cellular or
tissue response can be activated to cope with the condition.
Understanding how such a response is regulated on a mo-
lecular level may not only increase our knowledge about
fundamental biological processes during development, mat-
uration, and aging, but may also reveal new targets for the
treatment of sight-frightening diseases in human patients.
Factors in the HIF-activation pathway, HIF target genes and/
or proteins regulating tissue oxygenation itself may provide a
number of possibilities to support retinal cells and to maintain
normal retinal physiology and function.
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